A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP

HIV Infections Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00669487
• Other study ID #: SEARCH003
• Status: Completed
• Phase: Phase 3
• First received: April 24, 2008
• Last updated: May 27, 2015
• Start date: April 2008
• Est. completion date: April 2011

Study information

• Verified date: May 2015
• Source: South East Asia Research Collaboration with Hawaii
• Contact: n/a
• Is FDA regulated: No
• Health authority: Thailand: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This protocol aims to determine the risk/benefits of this policy by comparing head-to-head a regimen of GPO-VIR Z or TDF/FTC/NVP for 18 months in ARV-naïve patients to a 6-month lead in with GPO-VIR S followed by 12 months of GPO-VIR Z. The primary outcomes to be assessed will be anemia, neuropathy, lipoatrophy and renal function.

Description:

GPO-VIR Z is a new combination antiretroviral (ARV) medication that substitutes zidovudine (AZT) for stavudine (d4T) from the original formulation of GPO-VIR S. This new combination should decrease rates of lipoatrophy and neuropathy which are side-effects strongly linked to the use of d4T. However, there is some risk that initiating therapy with an AZT- containing regimen may cause unacceptable rates of anemia. Many Thai physicians have adopted a practice of using 6 months of the stavudine-containing GPO-VIR S as a lead in before introducing AZT-containing GPO-VIR Z in an effort to balance the risks and benefits of these two medications. There are no definitive data, however, that can attest to the benefit of such an approach.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: April 2011
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Documented HIV-1 infection

2. Age = 18 years old.

3. Subjects must be naïve to ARV. Individuals with past exposure to ARV associated with pregnancy will be allowed to enroll as long as the exposure is at least 3 months prior to entry.

4. CD4 < 350 cells/mm3

5. Subject understands the study and is able to sign informed consent

Exclusion Criteria:

1. Evidence of symptomatic persistent symptoms of tingling or numbness of lower extremities and bilateral lower extremity neuropathy on exam at entry. Abnormal exam includes 1) Diminished (compared with the knee) or absent ankle reflexes OR 2) Diminution of either vibration sensation in the legs (defined as perception of vibration for < 10 seconds at the great toe with a tuning fork initially struck hard enough to be audible) OR 3) Diminution of pin or temperature sensation in lower extremities OR 4) Contact allodynia in the feet.

2. Laboratory values 1) Absolute neutrophil count (ANC) < 750/mm3 2) Hemoglobin < 8.0 g/dL 3) ALT (SGPT) > 5 x ULN 4) Creatinine > 2 X ULN or < creatinine clearance < 30 cc per min by Cockroft-Gault formula

3. Active AIDS-defining opportunistic infection (OI) within 30 days prior to entry. Subjects must be off all acute treatments for OI for at least 14 days prior to entry. Subjects on maintenance or prophylactic therapy for AIDS-related OIs will be eligible.

4. Any immunomodulator, HIV vaccine or investigational therapy within 30 days of study entry

5. Pregnancy or breast-feeding; intent to become pregnant during the course of the study.

6. Presence of any active malignancy.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
• AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
• AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72

Locations

Country	Name	City	State
Thailand	SEARCH Thailand	Bangkok

Sponsors (4)

Lead Sponsor	Collaborator
South East Asia Research Collaboration with Hawaii	Queen Savang Vadhana Memorial Hospital, Thailand, Thai Red Cross AIDS Research Centre, University of Hawaii

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in mean hemoglobin at 24 weeks and 72 weeks		72 weeks	Yes
Primary	Proportion of participants with peripheral neuropathy at 24 weeks and 72 weeks		72 weeks	Yes
Secondary	Changes from baseline in body weight, limb fat, and lean body mass by DEXA scan at 24 weeks and 72 weeks		72 weeks	Yes
Secondary	Change from baseline in serum creatinine at 24 weeks and 72 weeks		72 weeks	Yes
Secondary	Proportion of participants with plasma HIV-1 RNA less than 50 copies/mL at 24 weeks and 72 weeks		72 weeks	No
Secondary	Change from baseline in CD4 count at 24 weeks and 72 weeks		72 weeks	No